Conference Schedule

When showcasing the impact of patient advocacy, it’s essential to highlight measurable outcomes. The key question is: how are we defining and measuring success? Is success reflected in the growth and evolution of the advocacy community itself? In the ability of patients to engage meaningfully with care teams? In their improved understanding of, and ability to live with, their diagnosis? Each of these factors demonstrated value for patients and the organization. The challenge lies in clearly articulating this impact to senior leadership in ways that resonate and ensure lasting buy-in. How can you articulate the value of advocacy to your senior leadership team?

  • Demonstrate different ways to measure the value of patient advocacy
  • Examine how to work with cross-functional teams to ensure advocacy is prominent in every team

Advocacy thrives when it is embraced across the organization and not just within a single department. Yet legal, compliance, marketing, and communications teams can sometimes be hesitant to engage, creating barriers to patient-centered progress. A Lucid report found that 78% of employees believe that their company’s leadership could do more to promote collaboration within their organization. How can you build trust, demonstrate value, and embed advocacy strategies to ensure alignment in your company?

  • Understand the value of working with cross-functional teams
  • Find ways to show value and how to utilize advocacy
  • Strategize how to engage teams that may be reluctant to collaborate.

When conducting clinical trials, it is widely agreed that some form of compensation to patients is appropriate. However, things become trickier when dealing with trials that require more time and resources from the patient. Lazarex Cancer Foundation stated, “Travel costs remain one of the top barriers to cancer clinical trials, leaving a staggering 93% of cancer patients without the help they need to participate.” While compensation can increase participation and address potential financial burdens, it also raises questions about incentivization and the potential for biased enrollment.

  • Go over the complexities tied to compensation for patients
  • Determine what is an appropriate and fair compensation

Patient advocacy has always been a driving force for change—but the way advocacy shows up is evolving. For decades, nonprofit patient advocacy organizations have led with credibility, stewardship, and deep-rooted connection to patient communities. Today, they are joined by a rising wave of individual patient leaders, influencers, and digital storytellers whose reach and immediacy are reshaping the public conversation. These new voices are not replacing the old— they’re adding dimension, urgency, and complexity to what it means to advocate.

  • Explore how advocacy is evolving—and why this shift matters to patients, caregivers, and the system
  • Go over the enduring role of nonprofit organizations in legitimacy, collective action, and policy advancement
  • Discover the rising influence of individual advocates in accelerating awareness, storytelling, and community activation
  • Understand legal, compliance, and funding considerations:
  • Look to the hybrid future: What does collaboration look like between traditional and emerging advocacy voices?

Rare disease patients face unique challenges in understanding their health and accessing effective treatments. Emerging applied technologies—such as wearables and AI-driven data analysis - are reshaping how patients track symptoms, understand why they don’t feel well, and improve quality of life in real time. At the same time, media platforms play a powerful role in uniting communities, driving education, and influencing policy. How can technology and media accelerate scientific outcomes, foster patient empowerment, and create new opportunities for innovation in rare disease care

  • Explore how applied technologies can deliver real-time insights into patient well-being and advance scientific outcomes.
  • Understand the psychological and quality-of-life benefits of empowering patients with knowledge about their condition.
  • Examine how media can bring rare disease communities together, strengthen education, and influence policy to support better patient outcomes.

This session explores how one company collaborated with a global network of patient advocates and families to co-create a robust suite of awareness and participation materials for their clinical trials. Because the studies span multiple age groups, the development process required careful tailoring to ensure materials would be age-appropriate, accessible, and meaningful for children, adolescents, and care partners alike.

  • Gain insight into the perceived pain points and gaps with current recruitment and participation support materials
  • Discover practical strategies for creating resources that support informed decisionmaking and strengthen patient and family engagement in clinical research

Engaging patients early in the trial process is no longer just a best practice but an expectation. Based on a study by Rare Revolution, trials that integrate patient input into protocol design can significantly reduce protocol amendments—amendments affect over 60% of trials and cost up to $500,000. But how early is “too early,” and what role should patients play in shaping protocol design? How can you form patient advisory committees and integrate patient perspectives into trial guidelines? Oftentimes, the FDA wants to see that patients are involved at every stage of a trial, what are the best ways to demonstrate that collaboration?

  • Discuss how to show the FDA you are creating a drug that meets unmet needs
  • Navigate how to include patients in clinical trials from the beginning stages
  • Allow patients to look through the trial guidelines to determine if they are too burdensome

Collaborating with patient advocacy groups is key to understanding patient needs and shaping better clinical and product outcomes. But how can organizations engage PAGs effectively while remaining compliant, from product development through clinical trials? How can you build strong, ethical partnerships that amplify the patient voice?

  • List the benefits of collaborating with patient advocacy groups across the product lifecycle
  • Acquire strategies for compliant engagement with PAGs during both development and clinical trials
  • Go over practical approaches to integrate patient insights into organizational decisionmaking and trial design

Day 1 Concludes at 5:15 PM

While US teams often lead with patient advocacy and community engagement, global teams face different challenges in integrating patient perspectives across diverse portfolios and regulatory environments. Despite perceived differences, the core goals remain the same, ensuring that patient voices shape development and access worldwide. How can US and global teams better align and collaborate and what obstacles are in the way?

  • Discover strategies for stronger alignment between US and global advocacy teams.
  • Explore common challenges and practical solutions for integrating patient perspectives across regions.

The current political climate has made diversity, equity, and inclusion in clinical research a sensitive subject, with some organizations retreating from the language of equity altogether. Yet avoiding these conversations risks undermining patient trust and failing to meet the needs of underrepresented populations. A recent national poll from the PAN Foundation’s Center for Patient Research finds that over the past 12 months, 1 in 4 adults with any chronic health condition have advocated for policy, legislation, and/or regulation to improve access to healthcare. How can companies and patients responsibly navigate political pressures in order to advocate for what they want?

  • Know the risks of diminishing DEI efforts in clinical studies and the potential impact on patients
  • Develop strategies to maintain patient trust and ensure inclusive, patient-centered research in challenging environments
  • Strategize ways for patients to advocate for improved healthcare access

The pharmaceutical industry is undergoing a shift from traditional HCP-focused marketing toward more patient-centric models. With patients becoming increasingly proactive and informed about their health, pharma companies must evolve their strategies to engage directly with them. How can means such as direct-to-patient strategies build a stronger marketing plan?

  • Strategize how to integrate digital tools in the marketing design
  • Explain the pros and cons associated with direct to patient marketing
  • Recognize the emerging role of influencer partnerships and what to consider when using them to reach patients

  • Debate patient involvement in Phase 3 clinical studies
  • Weigh the pros and cons of decentralized trials regarding equity, cost, and convenience
  • Engage ambassadors inside your company to support the advocacy agenda and ensure buy in
  • Discuss the importance of Patient Communities in clinical research and drug development

Including patients as co-authors on manuscripts is a powerful way to validate the patient perspective and highlight their lived experience. A survey of medical journal editors published in the NIH revealed that 69.2% view the inclusion of patient partners as authors on manuscripts as appropriate. This can improve the design of clinical trials and optimize care by enhancing our understanding of their personal experience with the disease. How can the patients work with different teams such as legal and compliance? What are the challenges from an industry and patient perspective?

  • Grasp the value of patient co-authorship in amplifying advocacy and strengthening scientific publications
  • Learn how to navigate legal and compliance considerations
  • Build new strategies for cross-functional collaboration to embed patient voices into research

Returning individual clinical trial results to research participants is evolving from an uncommon practice to a standard expectation that promotes ethical research and builds trust. Your team needs to understand the balance between the participant’s right to information and the practical challenges of data return for all stakeholders.

  • Discuss why patients want their individual trial results
  • Discover best practices for determining which data can be shared and when, and practical tools to facilitate the process

Artificial intelligence is increasingly shaping how patients are engaged and supported throughout clinical trials. It can be used to enhance efficiency and even as a component for diagnosis especially in rare disease. The NIH published a study that showed, “based on randomized clinical trials, AI-based tools improved medication adherence ranging from 6.7% to 32.7% compared to any intervention controls and current practices.” How can AI enhance patient experiences and improve trial outcomes?

  • Go over the role of AI in disease diagnosis and patient engagement
  • Explore current applications of AI in clinical trials
  • Discuss common challenges and pitfalls associated with integrating AI into patient advocacy efforts

Conference Concludes